A contamination control strategy for non-sterile products is no longer a voluntary exercise reserved for sterile sites that want to go the extra mile. With the Q&A published by EMA on 13 July 2026 (EMA/INS/GMP/161750/2026), the European authorities have spelled out which technical and organisational measures a manufacturer of non-sterile dosage forms — oral liquids, creams, ointments, tablets, low-bioburden intermediates — should consider to prevent microbial contamination. The message to inspectorates is clear: Annex 1 principles, QRM and CCS in particular, apply "appropriately" beyond the sterile perimeter. In this article we look at what the Q&A says, which regulatory bases it rests on, and how to build a proportionate CCS for a non-sterile site.
Why a contamination control strategy for non-sterile products
The starting point is the scope of Annex 1 (2022): the document states that its principles and guidance may be used to support the manufacture of other products that are not intended to be sterile — such as certain liquids, creams, ointments and low-bioburden biological intermediates — where the control of microbial, particulate and endotoxin/pyrogen contamination is considered important. It is not a formal obligation extended to all non-sterile manufacturing, but a methodological signpost: the conceptual framework — risk assessment, critical control points, verification of control effectiveness — is transferable.
The 2026 EMA Q&A closes the loop. Asked which technical and organisational measures should be considered to prevent microbial contamination of non-sterile medicinal products, the Agency explicitly points to Chapter 5 of EudraLex Volume 4 (notably sections 5.10 and 5.17–5.22 on prevention of cross-contamination), Annex 15 for validation and, indeed, Annex 1 principles applied proportionately to the non-sterile context. For anyone who treated microbiological contamination of non-sterile products as a "second-tier" topic compared with sterility assurance, this is a change of perspective: microbiological risk must be governed through a documented strategy, not scattered controls.
What the EMA Q&A asks for: technical and organisational measures
The Q&A distinguishes two families of measures which together form the backbone of a non-sterile CCS.
On the technical side, EMA lists among others: design of facilities and material flows that minimise contamination risk; cleaning validation that includes microbiological surface sampling, not only chemical testing; evaluation of suppliers of detergents and cleaning agents; control of expiry dates of prepared cleaning solutions; inclusion of equipment drying steps to avoid residual humidity (an ideal breeding ground for microbial proliferation); validated microbiological test methods for APIs, excipients, water, packaging materials, equipment, environments and finished product.
On the organisational side, the Q&A recalls: gowning procedures appropriate to the risk (gloves and face masks during critical operations, glove disinfection before entering critical areas); practical, recurring training on gowning, hygiene and behaviour in production; monitoring of personnel hygiene and health status; an environmental monitoring programme commensurate with the risk of the process and the product.
Topics like this one — new Q&As, annex revisions, regulatory deadlines — land every week in The Pragmatic GMP, GuideGxP's free newsletter: practical, audit-ready analysis with zero fluff. Subscribe so you don't miss the next contamination-control update.
From Annex 1 to non-sterile: adapting the CCS elements
Annex 1 describes the CCS as a strategy implemented across the facility to define all critical control points and assess the effectiveness of all the controls (design, procedural, technical and organisational) and monitoring measures. The list of elements in section 2.5 was written for sterile manufacturing, but most of it translates directly to the non-sterile world, with different acceptance criteria. The table below shows some examples of that transposition.
| CCS element (Annex 1) | Sterile-product reading | Non-sterile-product reading |
|---|---|---|
| Design of plant and processes | Grade A/B, barriers (RABS/isolators), first air | Material and personnel flows, dedicated areas, equipment drying |
| Utilities (water first of all) | WFI, endotoxin control | Purified water suitable for use, loop sanitisation, microbiological trending |
| Cleaning and disinfection | Sterile disinfectants, sporicidal rotation | Cleaning validation with microbiological recovery, solution expiry dates, qualified suppliers |
| Personnel | Aseptic gowning qualification, APS | Risk-based gowning, hygiene and health, behavioural training |
| Environmental monitoring | Continuous particle and microbial monitoring in Grade A | Risk-based EM at critical points, alert/action limits and trending |
| Product and materials | Sterility assurance, container integrity | Bioburden of raw materials and product, microbiological specifications, objectionable organisms |
The guiding criterion is proportionality: no inspector expects continuous monitoring in a tablet-compression room. They do expect the site to be able to say where the product can become contaminated, which controls guard those points and how their effectiveness is verified over time. That is exactly the critical-control-point logic of the CCS.
Typical mistakes at non-sterile sites
In audit practice, findings on contamination control at non-sterile sites cluster around a few recurring patterns:
- Controls that exist but are not connected: EM, cleaning validation, water qualification and training live in separate documents, with no summary document linking them to product risks.
- Chemical-only cleaning validation: carryover limits are calculated, but there is no microbiological surface sampling and no data-supported dirty/clean hold times.
- Equipment stored wet: no drying steps and no verification of residual humidity after washing.
- Cleaning solutions without expiry dates: detergents and solutions prepared on site used beyond their microbiological stability.
- Underestimated gowning: gloves not disinfected, no face masks during steps with exposed product, training that is purely theoretical.
- "Photocopy" EM: sampling points inherited from site history and never re-assessed through a risk assessment.
GuideGxP recommendation
The most efficient way to respond to the EMA Q&A is not to create new documents but to federate the existing ones. In practice: (1) start from a process map identifying the entry points of microbial contamination, from material receipt to primary packaging; (2) build a risk–control–verification matrix linking each critical point to the technical and organisational controls already in place, highlighting gaps against the measures listed by EMA; (3) formalise everything in a lean CCS document with owners, KPIs (EM trends, bioburden results, microbiological deviations) and a periodic review cycle within management review. A site that presents this structure during an inspection demonstrates that it governs risk rather than suffering it.
If you want to start from a ready-made framework, our Contamination Control Strategy (CCS) Operational Guide for GMP includes the complete framework, the Word/Excel toolkit templates and examples for adapting the CCS to non-sterile contexts too.
Official sources
- EMA Q&A – Technical and organisational measures to prevent microbial contamination of non-sterile medicinal products (EMA/INS/GMP/161750/2026)
- EudraLex Volume 4 – Annex 1: Manufacture of Sterile Medicinal Products (C(2022) 5938 final)
- EudraLex Volume 4 – EU Guidelines for Good Manufacturing Practice (Chapter 5, Annex 15)
